Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study

J Clin Oncol 29: 2011 (suppl. abstr 531) – 2011 ASCO Annual Meeting

P. Viens, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. Roché, M. Pavlyuk, T.D. Bachelot, E. Charafe-Joffret

Vous souhaitez échanger
avec nos équipes

D’autres articles qui pourraient
vous intéresser

Use of Digital Health Technology to Enable Drug Development

Oncologie

Use of Digital Health Technology to Enable Drug Development

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

Oncologie

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

Primary efficacy analysis of a phase II study of neoadjuvant Bevacizumab, chemotherapy, and Trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY 2 study

Oncologie

Primary efficacy analysis of a phase II study of neoadjuvant Bevacizumab, chemotherapy, and Trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY 2 study